1 A zebra®sh M 2 muscarinic acetylcholine receptor (mAChR) gene was cloned. It encodes 495 amino acids in a single exon. The derived amino acid sequence is 73.5% identical to its human homologue. 2 Competitive binding studies of the zebra®sh M 2 receptor and [ 3 H]-NMS gave negative log dissociation constants (pK i ) for each antagonist as follows: atropine (9.16)4himbacine (8.05)54-DAMP (7.83)4AF-DX 116 (7.26)5pirenzepine (7.18)5tropicamide (6.97)5methoctramine (6.82)5p-F-HHSiD (6.67)4carbachol (5.20). The antagonist anity pro®le correlated with the pro®le of the human M 2 receptor, except for pirenzepine. 3 Reverse transcription polymerase chain reaction and Southern blotting analysis demonstrated that the M 2 mAChR mRNA levels increased during the segmentation period (12 h post-fertilization; h.p.f.) in zebra®sh. By whole-mount in situ hybridization, the M 2 mAChR was ®rst detectable in the heart, vagus motor ganglion, and vagus sensory ganglion at 30, 48 and 60 h.p.f., respectively. 4 The muscarinic receptor that mediates carbachol (CCh)-induced bradycardia was functionally mature at 72 h.p.f. The eect of CCh-induced bradycardia was antagonized by several muscarinic receptor antagonists with the order of potency (pIC 50 values): atropine (6.76)4methoctramine (6.47)4himbacine (6.10)44-DAMP (5.72)4AF-DX 116 (4.77), however, not by pirenzepine, p-FHHSiD, or tropicamide (510 mM). 5 The eect of CCh-induced bradycardia was abolished completely before 56 h.p.f. by M 2 RNA interference, and the bradycardia eect gradually recovered after 72 h.p.f. The basal heart rate was increased in embryos injected with M 2 mAChR morpholino antisense oligonucleotide (M 2 MO) and the eect of CCh-induced bradycardia was abolished by M 2 MO in a dose-dependent manner. In conclusion, the results suggest that the M 2 mAChR inhibit basal heart rate in zebra®sh embryo and the M 2 mAChR mediates the CCh-induced bradycardia.
Introduction
Muscarinic acetylcholine receptors (mAChRs) are members of the superfamily of G-protein-coupled receptors with seven putative transmembrane domains. On the basis of molecular biological characterization, ®ve subtypes (M 1 ± M 5 ) of mAChR genes have been identi®ed (Bonner et al., 1988; Liao et al., 1989) , with each of these receptor proteins encoded by an intronless gene exhibiting a unique pharmacological pro®le (Bonner et al., 1988; Peralta et al., 1987a) . The mAChRs can be divided into two groups according to their biological function. M 1 , M 3 and M 5 preferentially stimulate phospholipase C activity, whereas M 2 and M 4 mAChR are also expressed in cardiac tissue. A signi®cant amount of M 3 , M 4 , and M 5 can also be found in the chicken heart (Creason et al., 2000; McKinnon & Nathanson, 1995) , and all ®ve subtypes of the mAChRs are expressed in the human heart (Wang et al., 2001) .
The zebra®sh is a new model system for studies of vertebrate development and genetics. External development and optical clarity during embryogenesis provide advantage with respect to visual analysis of early developmental processes. The zebra®sh is particularly amenable to the study of cardiac function such as changes in heart rate, which can be directly observed under a stereomicroscope. Besides, it is easy to inject the circulatory system of zebra®sh embryos with trace compounds. All these advantages make the zebra®sh a good in vivo model for the analysis of the eects of agonists and antagonists on the heart rate regulation. The zebra®sh's high fecundity and short generation time further facilitates genetic analysis. Hundreds of mutant zebra®sh phenotypes have been identi®ed (Nusslein-Volhard, 1994 ) and many of these resemble human clinical disorders. Some studies indicate that double-stranded RNA interference (RNA i ) can inhibit gene expression in the zebra®sh (Wargelius et al., 1999; Li et al., 2000) and that morpholino-modi®ed antisense oligonucleotides (MOs) are eective and speci®c translational inhibitors in zebra®sh embryos (Nasevicius & Ekker, 2000) . The creation of critical genetic reagents and methods, coupled with the rapid progress of the zebra®sh genome project, is bringing this model system to its full potential for the study of vertebrate physiology, pharmacology, and human diseases (Dooley & Zon, 2000) .
In this paper, we described the cloning and pharmacological characterization of the zebra®sh M 2 mAChR. We studied the expression patterns and functional maturation of the M 2 mAChR during embryogenesis. We established an in vivo assay system to test drugs that act on mAChRs. We also critically investigated the role of M 2 mAChR in the regulation of heart rate in zebra®sh by RNA i and MO gene knockdown methods. These approaches can be applied to all receptors that play roles in heart rate regulation.
Methods

Animals
Zebra®sh (Danio rerio) were obtained from Dr D. Barnes's laboratory (Oregon State University Corvallis, OR, U.S.A.) in 1996 and thereafter bred and reared in the Zebra®sh Room, Institute of Zoology at 25 ± 308C under 14 h : 10 h light ± dark conditions. Embryos were raised in a 28.58C incubator and stated as described by Kimmel et al. (1995) . Fertilized eggs were obtained from 3 ± 9-month-old parents. Embryos more than 24 h old were treated with 0.003% phenylthiourea in 10% Hank's solution (Wester®eld, 1994) to prevent melanin formation.
Cloning of the zebrafish mAChR genes
To clone the zebra®sh mAChR genes, genomic DNA were prepared from adult male zebra®sh, and ampli®ed by PCR with the degenerated forward primer 5'-TGGYTIGCIYTIGAY-TAYBTIGC-3' and the reverse primer 5'-RATRTTRTAIG-GIGTCCAIGT-3'. The PCR reaction was performed under the following conditions: 35 cycles at 948C for 30 s, at 608C for 30 s and at 728C for 1 min; a ®nal extension at 728C for 10 min and a ®nal holding at 48C. Two DNA fragments were ampli®ed and cloned into the pGEM-T vector for DNA sequencing. After DNA sequencing, one 980-bp fragment was identi®ed as the putative zebra®sh M 2 mAChR, and the other 920-bp fragment was identi®ed as the putative M 5 mAChR. The 980-bp fragment was used as a template to synthesize a 32 P-labelled probe for screening of a zebra®sh genomic DNA library (Provided by Dr C.Y. Chang, Institute of Zoology). The genomic DNA library was consutructed in the FIX lambda vector (Stratagene, La Jolla, CA, U.S.A.). The recombinant phages were ampli®ed with E. coli XL1 Blue MRA (P2) (Stratagene), and plated and screened exactly as described previously (Liao et al., 1989) . A Marathon TM cDNA ampli®ca-tion kit was used for rapid ampli®cation of cDNA ends (RACE) of the M 2 mAChR. The manufacturer's protocol was followed. The 5'-RACE sequence was used for the design of the double-stranded RNA (dsRNA) and MOs.
DNA sequencing and analysis
After puri®cation of the hybridizing phage DNA, DNA sequencing was carried out with an ABI prism 377 automated DNA sequencer (Applied Biosystems, Foster City, CA, U.S.A.). The DNA sequence and the deduced amino acid sequence were analysed for similarity to known sequences throught the NCBI Blast Network Service. The MAP, PILEUP, FASTA, and BESTFIT programs from the Wisconsin sequence analysis package of the Genetics Computer Group (GCG) were also used.
Transfection of Ltk
7 cells with zebrafish mAChR expression plasmid DNA The recombinant phage DNA encoding the complete open reading frame of the zebra®sh M 2 mAChR was ampli®ed by PCR (forward primer: CGGAATTCGCGAGCTCAC-CATGGATACAAT; backward primer: CGAGATCTG-TGTGTGAGTGTGTGTAAGCGG) and subcloned into an expression vector pcDNA3.1/Neo (Invitrogen, Carlsbad, CA, U.S.A.) as pcDNA ± zM 2 . Murine Ltk-cells was grown in Medium Essential Medium Alpha Medium containing 10% foetal calf serum, 100 U ml 71 penicillin, 100 mg ml 71 streptomycin and maintained in a 5% CO 2 environment at 378C. Cells seeded at 1610 5 cells per well in 6-well multidishes were transfected with pcDNA-zM 2 plasmid DNA by the lipofectamine method 48 h after plating following the manufacturer's procedure. The medium was replaced 24 h after transfection, and 400 mg ml 71 G418 was added 24 h later. Stable cell clones were transferred to 24-well plates, then were expanded to 6-well plates and con®rmed by a receptor binding assay using [ 3 H]NMS as the radiolabelled ligand following the procedure described previously (Liao et al., 1989 
Saturation binding and competition-binding assays
A saturation-binding assay was performed using nine concentrations of [ added to the LzM 2 cells grown to con¯uence in 6-well plates as described previously (Liao et al., 1989) . Nonspeci®c binding of [ 3 H]NMS was de®ned as the radioactivity bound to intact cells in the presence of atropine (1 mM). Linear regression was performed, and the correlation coecient (r) was calculated using Sigma-Plot. The results were analysed on a Scatchard plot that allows the calculation of the B Max and the K D . The values represent the average of duplicate measurements performed on four individual preparations.
Competition-binding assays with various antagonists were carried out as described previously (Liao et al., 1989) . LzM 2 cells was incubated with 1 nM [ 3 H]NMS medium containing various concentrations of AF-DX 116, atropine, CCh, 4-DAMP, p-F-HHSiD, himbacine, pirenzepine, or methoctramine, respectively. The follow-on reaction was continued as described above from the saturation-binding assays. Competition experiments were analysed using Sigma-Plot. Antagonist inhibition experiments were analysed by nonlinear curve ®tting using the least-squares method, with K i being calculated by the method of Cheng & Pruso (1973) 
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. To ensure the validity and accuracy of the competitive binding assays, linear regression was performed on the per cent bound versus the ratio of bound over free ligand, and only data with regression coecients of 40.9 were accepted for analysis.
Heart rate measurements
Zebra®sh embryos of dierent development stages were collected, and the heart rate was measured. This was done by visually counting the heartbeats on a colour monitor, which transmitted images from an SZH dissecting microscope (Olympus, NY, U.S.A.) by CCD (JVC, Tokyo, Japan). Microelectrodes with 2-to 5-mm tips were made by pulling glass capillaries (1 mm OD) with a glass microelectrode puller (model PA91, Narishige Scienti®c Instrument, Tokyo, Japan) and a microgrinder (model EG-400, Narishige Scienti®c Instrument, Tokyo, Japan). The zebra®sh embryos were anaesthetized with 0.64 mM tricaine (Sigma Chemical Co., St. Louis, MO, U.S.A.) in embryo medium as described by Wester®eld (1994) for 3 min and held for injection using a holding pipette applied to the side of the yolk. About 0.7 nl of CCh (1 mM) with or without dierent concentrations of antagonists was injected into the right common cardinal vein near the pectoral ®n bud by the microelectrode connected to the pressure injection apparatus (model PLI-188, Nikon, Garden City, NY, U.S.A.). In order to control the injection volume, phenol red (®nal 0.2%) was used to dilute the drugs. Phenol red alone did not in¯uence the embryonic heart rate (data not shown). After injection and for 3-min circulation, the heart rate reached a plateau and was regular. And then the heartbeats were counted for another 1 min with the aid of a counter and a timer. The embryos were then returned to the embryonic medium without tricaine for recovery. The zebra®sh heart rate gradually returned to control levels within 30 min. It means that the drugs were cleared or inactivated in a given zebra®sh. All experiments were carried out at a room temperature of 258C. The cardiac output of zebra®sh (72 h.p.f.) is 50 nl min 71 (Fritsche et al., 2000) and the heart rate is 142 beats min
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. The injection volume (0.7 nl) is almost equal to two stroke volumes. We observed that it takes about 20 heartbeats for the injected dye to accomplish one circulation. Therefore, the blood concentration of drugs was estimated to be 10 fold diluted than the injection concentration.
Reverse transcription polymerase chain reaction (RT ± PCR) and Southern blotting
When dierent development stage embryos were collected, they were rinsed in ice-cold phosphate buer saline (mM: NaH 2 PO 4 20, NaCl 150, pH 7.4) and immediately frozen in liquid nitrogen. Total RNA was isolated from these samples using TRIZOL reagent, a phenol/chloroform extraction, and ethanol precipitation. Reverse transcription was performed with oligo-dT primer with 1 mg of total cellular RNA used to synthesize ®rst-strand cDNA using a ®rst-strand TM cDNA synthesis kit. Two microlitres of the cDNA reaction was used in each PCR reaction. PCR was performed with the zebra®sh M 2 -speci®c primers (sense: 5'-CGAAGATGGCAGGAATG-ATGAT-3', antisense: 5'-CATTGGCTGCTGCTGACGAG-GG-3'). PCR was run as 35 cycles at 948C for 30 s, at 658C for 30 s, and at 728C for 1 min, with a ®nal extension at 728C for 10 min and holding at 48C. RT ± PCR for a-actin was conducted the same as described above except that one pair of a-actin-speci®c primers was used. They are 5'-TCA-CACCTTCTACAACGAGCTGCG-3' and 5'-GAAGCTG-TAGCCTCTCTCGGTCAG-3'. The PCR products were analysed by electrophoresis on a 1.2% agarose gel and subsequently visualized with ethidium bromide using a gel documentation system. The total RNA concentration was determined spectrophotometrically (Hitachi U-2000) .
Southern blot analysis of the RT ± PCR products was performed as described earlier (Hwang et al., 1997) . Membranes were prehybridized for 2 h in the prehybridization buer (50% formamide. 56SSC, 0.5% SDS, 1% blocking solution, and 0.5% sodium lauroyl sarcosine) at 428C. Hybridization was conducted in prehybridization buer containing 25 ng ml 71 of 1.5 kb digoxigenin (DIG)-labelled DNA probes at 428C overnight. CSPD chemiluminescence detection was conducted following the manufacturer's protocol (Roche Applied Science, Mannheim, Germany).
Whole-mount in situ hybridization
DIG-labelled riboprobes were prepared from a pcDNA3.1/ Hygro plasmid harbouring the sense or antisense M 2 receptor coding region following the manufacturer's protocols (Roche Applied Science). T7 RNA polymerase was used for in vitro transcription of all probes. Whole mount in situ hybridization was based on the method described by Chen & Fishman (1996) . Embryos were ®xed in 4% paraformaldehyde (PFA) in phsophate-buered saline (PBS) at 48C overnight, rinsed in PBS and manually dechorionated. Embryos were dehydrated in 100% methanol and stored at 7208C. In the beginning, embryos were rehydrated in a graded series of 75%, 50%, 25% methanol/PBS containing 0.1% Tween-20 (PBST), and washed in PBST. The embryos were treated with proteinase K (5, 10, 15, 25 and 50 mg ml
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, 25 min for 30, 36, 48, 60 and 72 h.p.f. embryos, respectively) to facilitate the probe penetration during in situ hybridization. Embryos were re®xed in 4% PFA for 20 min, washed with PBS, and incubated in 1 ml of 0.1 M triethanolamine containing 2.5 ml acetic anhydride for 1 h. After washing, the embryos were incubated in hyb-buer (50% formamide, 56SSC, 0.1% Tween 20, pH 5.0) at 688 for 5 min, and prehybridized with hyb + -buer (hyb-buer plus 500 mg ml 71 yeast tRNA and 50 mg ml 71 heparin) at 688C for 2 h. The hybridization was performed with sense or antisense M 2 DIG-labelled probes at 688C for 60 h. Then the embryos were washed in a series of 75, 50, 25% hyb-buer/26SSC, 26SSC and 0.26SSC at 688C followed by washing in a series of 75, 50, 25% 0.26SSC/PBST at room temperature. Embryos were immersed in blocking solution (PBST containing 2 mg ml 71 bovine serum albumin and 5% sheep serum) for 2 h and incubated with pre-absorbed anti-DIG-alkaline phosphatase (1 : 2000 in blocking solution) for 2 h. After washing with PBST, the embryos were incubated with freshly made detection buer (0.1 M Tris-HCl, pH 9.5, 50 mM MgCl 2 , 0.1 M NaCl, 0.1% Tween-20) and colour development was carried out using detection buer containing NBT/BCIP. The reaction proceeded for 3 ± 4 h. After colour development, embryos were ®xed in 4% PFA, mounted in 50% glycerol and photographed under a stereomicroscope.
Synthesis and microinjection of dsRNA
To prepare dsRNA for injection, a 174-bp M 2 5'UTR sequence was ampli®ed by PCR with the sense primer 5'-GAGAAGAGCTCCGACTGACCGTC-3' and reverse primer 5'-TGGTGAGCTCGCTCAGGTACAG-3'. This fragment was then subcloned into the pGEM-T Easy vector. A 742-bp EGFP fragment from the pEGFP-1 vector was subcloned into the NotI and BamHI restriction sites of the pcDNA3.1/Hygro vector. Synthesis and annealing of the dsRNA were performed essentially as described by Li et al. (2000) . The l-cell-stage embryos were microinjected with 100 fg (M 2 ) or 430 fg (EGFP) dsRNA (approx 5.25610 6 molecules) under a dissecting microscope with pulled microcapillary pipettes to deliver the dsRNA solution. In order to control the injection volume, phenol red (®nal 0.2%) was used to dilute the dsRNA products. The injected embryos were subsequently incubated in embryo medium at 28.58C. Finally, the heart rate was measured as described above.
Microinjection of MOs
The MOs were obtained from Gene Tools, LLC (Philomath, OR, U.S.A.). The selected sequences were based on design parameters according to the manufacturer's recommendations, namely 25-mer MOs of *50% G+C content with no predicted internal hairpins. Sequences were as follows: M 2 MO, 5'-CACTCAGATCGCTATTGGCAGGACG-3'; oligonucleotide with four mismatch base (M 2 4 mp MO) was used as control for M 2 MO, 5'-CACTCAGATGGCTATTCG-CACGTCG-3'. MOs were solubilized in water at the concentration of 5 mM (*40 mg ml 71 ). The stock solution was diluted to a working concentration with water and phenol red before injection as described above. The l-cellstage embryos were injected with one of four solutions at dierent dose concentrations (10, 100, 300, 1000 mM) and the injected volume was about 1 nl. This was equivalent to 0.08, 0.8, 2.4 and 8 ng per embryo. The heart rate was then measured as described above. Higher doses (8 ng per embryo) of the M 2 MO resulted in phenotypic changes (data not shown) in about 50% of ®shes, which were not measured for heart rate. 
Results
Cloning of the zebrafish M 2 mAChR gene and amino acids alingment
To clone the muscarinic acetylcholine receptor, PCR was performed on zebra®sh genomic DNA using degenerate primers based upon conserved residues of transmembrane domain IV and transmembrane domain VII. Agarose gel electrophoresis demonstrated the presence of two bands. The ampli®ed fragments were cloned into the pGEM-T Vector for sequencing. Sequence analysis demonstrated that these fragments show a higher sequence identity to M 2 and M 5 (data not shown) mAChR. The fragment of M 2 mAChR was used as a probe to screen a genomic zebra®sh library in order to isolate a full-length clone encoding the zebra®sh M 2 mAChR. Several positive phage clones were obtained from genomic library and a number of the clones were sequenced. The predicted amino acid sequence encoded by the putative M 2 proteins was 495 amino acids. The entire coding region sequence corresponding to the M 2 -subtype mAChR is shown in Figure 1a 
Pharmacological characterization of M 2 mAChR in transfected cell line
To con®rm that the genomic clone encodes a functional mAChR, the expression construct pcDNA-zM 2 containing the entire coding region was transfected into murine Ltk (Figure 2a) . The anity of the zebra®sh mACHR for several mAChR antagonists was determined by a series of competitive receptor binding assays. These equilibrium displacement studies were carried out with the mAChR antagonists as shown in Figure 2b . The rank order of the negative log dissociation constants (pK i ) for each antagonist was: atropine (9.16)4himbacine (8.05)54-DAMP (7.83)4AF-DX 116 (7.26)5pirenzepine (7.18)5tropicamide (6.97)5methoctra-mine (6.82)5p-F-HHSiD (6.67) ( Table 1) .
Expression patterns of the M 2 mAChR
The temporal expression of the zebra®sh M 2 mAChR transcripts was studied throughout embryogenesis from the early cleavage stages to 30 day (d.p.f.) using RT ± PCR and Southern blotting (Figure 3) . The M 2 mAChR was found at only trace levels before the segmentation period (12 h.p.f.). The M 2 mRNA was present at low levels at 12 h.p.f. and was obviously expressed by 24 h.p.f. In addition, the M 2 mRNA reached a maximum level between 3 ± 3.5 d.p.f. and slightly decreased at 30 d.p.f. By whole-mount in situ hybridization, the DIG-labelled antisense RNA hybridized with the endogenous mRNA. It showed that the M 2 mAChR was not expressed in the embryonic heart at 22 h.p.f. (Figure 4a) . At 30 h.p.f., the M 2 mAChR transcripts began to be visible in the heart ( Figure  4b ). The M 2 mAChR was detected bilaterally along the heart to the sinus venosus at 36 h.p.f. (Figure 4c ) and began to be expressed in the vagus motor ganglion at 48 h.p.f. (Figure 4d) . After 60 h.p.f., it was observed in the vagus sensory ganglion and mid-hindbrain (Figure 4e ) with further increase of expression at 72 h.p.f. (Figure 4f ).
Developmental regulation of zebrafish embryo heart rate by M 2 mAChR
In order to set up the zebra®sh embryo as a model for cardiac mAChR research, it was necessary to ®rst address the question of when the embryo heart is under mAChR regulation. Therefore the embryo heart rate changes during development were examined. The heart rates of the unrestrained embryos were measured directly under a stereomicroscope starting from the embryonic stage at 24 ± 168 h.p.f. From the pharyngula period (24 h.p.f.) to the hatching period (48 ± 72 h.p.f.), heart rate increased dramatically from The pKi values were calculated from the data shown in Figure 2b , and arranged according to the anity of the zebra®sh M 2 mAChR. Figure 5 ). When hatched embryos were anaesthetized with tricaine, the heart rate decreased signi®cantly at an early developmental stage but varied only slightly after 72 h.p.f. (Figure 5 ). When CCh was injected into the embryos at dierent developmental stages under tricaine anaesthesia, the bradycardia eect of CCh (100 mM) varied dramatically from partial inhibition (14.8+0.3% at 48 h.p.f., 58.7+3.2% at 56 h.p.f.) to maximal inhibition (79.7+2.2% at 72 ± 168 h.p.f.) ( Figure 5 , insertion panel). The antagonism of CCh-induced bradycardia was studied by co-injection with mAChR antagonists at 72 h.p.f. The pIC 50 values of antagonists, measured by antagonism of CCh-induced bradycardia in the zebra®sh heart, were atropine (6.76+0.11)4methoctramine (6.47+0.05)4himba-cine (6.10+0.04)44-DAMP (5.72+0.11)4AF-DX 116 (4.77+0.13). The bradycardia was not antagonized by pirenzepine, p-F-HHSiD, or tropicamide (510 mM) (Figure  6a,b) .
Effect of RNA i and MOs of M 2 mAChR on CCh-induced bradycardia
Because the embryo may contain more than one-subtype of mAChR, the pharmacological eects based on in vivo experiments may result from a mixture of mAChRs. In order to test this possibility, an RNA i technique was used to knockdown endogenous mAChR synthesis to test which is the major mAChR associated with the bradycardia eect in zebra®sh embryos. The eect of the control EGFP RNA i on CCh-induced bradycardia (Figure 7 ) was similar to those for the wild-type at three dierent developmental stages. However, M 2 RNA i blocks CCh-induced bradycardia by almost 100% at the 56 h.p.f. developmental stage. From the 72-h.p.f. stage, the RNA i eect is gradually lost; this is possibly due to degradation of the dsRNA. At the 96-h.p.f. stage, the RNA i eect of M 2 on CCh-induced bradycardia is still signi®cantly dierent from the wild-type and EGFP.
To con®rm the results, we used MO to knockdown the endogenous M 2 mAChR translation. Microinjection of M 2 MO increased the zebra®sh embryo basal heart rate in a dose-dependent manner but not the M 2 4 mp MO ( Figure  8a ). The M 2 MO also attenuates the CCh-induced bradycardia (Figure 8b ) in a dose-dependent manner. It can block CCh-induced bradycardia by 90.5+4.6% at a concentration of 8 ng per embryo. However, the M 2 4 mp MO had no in¯uence on the CCh-induced bradycardia.
Discussion
In the present study, we ®rst cloned a zebra®sh M 2 mAChR gene and expressed the M 2 mAChR in cell line for mAChR pharmacological characterization. The temporal and spatial gene expression pattern of the M 2 mAChR suggested it is involved in the regulation of heart rate. We then developed a functional assay to demonstrate that the machinery for CCh- DNase I treated total RNAs from the indicated developmental stages were used as a template for the RT ± PCR reaction. Equal aliquots of cDNA were ampli®ed with oligonucleotides speci®c for M 2 mAChR (582 b.p. product) or a-actin (341 b.p. product). Five ml of the RT ± PCR reaction products were loaded on a 1.2% agarose gel and stained with ethidium bromide as shown in ®rst panel (M 2 ) and second panel (a-actin). Southern blot analysis using a DIG-labelled M 2 mAChR DNA probe was carried out to con®rm the identity of the ampli®ed DNA as shown in the third panel. induced bradycardia matures in the 72 h.p.f. zebra®sh. By using the 72 h.p.f. zebra®sh heart as an in vivo bioassay system, we compared the mAChR antagonists' potency to block the CCh-induced bradycardia. Finally, by RNA i and MO knockdown methods, we demonstrated that the CChinduced bradycardia is mediated through the M 2 mAChR.
There are some notable features of the zebra®sh M 2 mAChR. Firstly, the human, pig, rat and chicken M 2 mAChR gene sequences all predict a polypeptide containing 466 amino acids (GenBank accession nos. P08172, P06199, P10980, and A40972, respectively), while the zebra®sh M 2 mAChR gene encodes a 495-amino-acid protein (Figure 1b) . Secondly, zebra®sh M 2 mAChR has the same three putative Nglycosylation sites as do the rat, pig, and chicken receptors, compared to four N-glycosylation sites in the human receptor. All these 5 M 2 mAChR genes share a common feature with several other members of the G-protein coupled receptor gene superfamily; their open reading frames are contained within a single exon. Rapid ampli®cation of cDNA ends (RACE) and sequence analysis of zebra®sh M 2 mAChR show that the coding sequence is contained in a single exon, as has been observed for mammalian mAChR (Caul®eld, 1993) .
To con®rm that the genomic clone encoded a functional mAChR, the entire coding region of the M 2 mAChR was expressed in stably transfected Ltk 7 cells for pharmacological characterization. The apparent dissociation constant for the binding of [ (Table 1) . However, the zebra®sh M 2 receptor binding anity for pirenzepine is higher than the mammalian M 2 receptor binding anity (Caul®eld & Birdsall, 1998) (Table 1) . It may be due to the presence of a threonine at the ligand binding site. In the human M 1 /M 2 chimeric receptors, each chimeric receptor that possesses a threonine (i.e., M 1 sequence) at the position corresponding to M 2 401 had a higher anity for pirenzepine than did the wild-type M 2 receptor (Kubo et al., 1988; Lai et al., 1992) . The M 2 receptor mutant (A401T) also expressed Figure 5 Heart rate changes and CCh-induced bradycardia during zebra®sh embryogenesis. The heart rate of zebra®sh embryos at dierent developmental stages were measured before and after being anaesthetized with tricaine. Fitted curved lines were plotted by a sigmoid 3 parameter model (Sigma-Plot). CCh-induced bradycardia (inner panel) was performed in vivo. Each embryo was anaesthetized with tricaine and microinjected with CCh. Heart rate was measured before and after CCh stimulation as described in Methods. The ratio of the heart rate (y-axis) represents the percentage of heart rate after CCh related to before CCh stimulation. All experiments were carried out at a room temperature of 258C. Each value represents the mean and s.e.mean from three independent experiments, each carried out on 8 ± 10 individuals. Absence of error bars indicates that the magnitude of the error is less than the symbol size. The dierences between before and after treatment were tested using the Student's ttest and P50.01 (* ,# ) was considered signi®cant. Dierent lower-case letters (a, b, c) indicate a signi®cant dierence (P50.01) among groups using the ANOVA and multiple range t-test. The ratio of the heart rate (y-axis) represents the percentage of heart rate after drug related to before drug injection. All results are expressed as the mean+s.e.mean derived from three independent experiments, each carried out on 3 ± 6 individuals. The dierences were tested using the Student's t-test and P50.05 (*) or P50.01 (**) was considered signi®cant.
British Journal of Pharmacology vol 137 (6) Zebrafish M 2 mAChR D.J.-Y. Hsieh and C.-F. Liaoenhanced anity for pirenzepine (Ellis & Seidenberg, 2000) . Furthermore, previous studies have shown that the chicken M 2 receptor, which also has a threonine at this position, has a signi®cantly higher anity for pirenzepine than does mammalian M 2 mAChR (Tietje & Nathanson, 1991) .
In close association with the neurotransmitter acetylcholine (ACh) are two enzymes, choline acetyltransferase and acetylcholinesterase (AChE), which are involved in its synthesis and hydrolysis, respectively. When ACh binds to the mAChR, the mAChR couples with G protein, then the bg subunit can bind to and directly opens a cardiac K + channel. All of these components are related to the mediation of the mAChR signal transduction to a biological response of heart contraction. There is an appearance of AChE in the ventrolateral hindbrain region and reiculospinal neurons (Hanneman et al., 1988; Ross et al., 1992) and g3 mRNA in the ventral hindbrain (Kelly et al., 2001) of zebra®sh embryos at late somitogenesis (18 ± 19 h.p.f.). The zebra®sh K + channel is functioning in a day 3 embryo (Baker et al., 1997) . From whole-mount in situ hybridization, M 2 mAChR transcripts were abundantly expressed in the sinus venosus and atrium (Figure 4c ) at 36 h.p.f. and it was visible in the vagus motor and sensory ganglion before 60 h.p.f. (Figure 4) . A recent study has indicated that, in the teleost heart, branches of the vagus nerves innervate the sinus venosus and atrium, causing bradycardia via muscarinic receptors (Preston & Courtice, 1995) . We have shown that with tricaine treatment, the heart rate was signi®cantly reduced at the 48 ± 56 h.p.f. embryos but not at 72 h.p.f. embryos and thereafter ( Figure 5 ). Tricaine can prevent transient increases in sodium ion permeability, thereby decrease excitability and block impulse conduction of nervous tissue (Letcher, 1992) . Besides, they also act as noncompetitive cholinergic antagonists (Nogrady & Keshmirian, 1986) . Thus tricaine may inhibit the zebra®sh heart rate by blocking sodium ion permeability in the early embryos before mAChR appearance. The inhibitory eect of tricaine on heart rate is reversed after 72 h.p.f. when the mAChR regulation of heart rate become mature ( Figure 5 ) and tricaine can function as a cholinergic antagonist. In CCh-induced bradycardia, we found that bradycardia occurred at 48 h.p.f. and reached a maximum at 72 h.p.f. The eect was blocked by atropine (Figure 6b ). From the results of both RT ± PCR and wholemount in situ hybridization, the temporal and spatial expression of M 2 mAChR suggests its involvement in the regulation of heart rate. We propose that the machinery and the muscarinic receptor subtypes, most likely the M 2 mAChR, which mediate CCh-induced bradycardia are functionally mature in the 72-h.p.f. embryonic heart.
Since the embryo heart may contain more than one-subtype of mAChR, the in vivo eect of CCh may result from the activation of multiple mAChRs. Although the M 2 subtype is Figure 7 Eects of M 2 and EGFP RNA i on CCh-induced bradycardia in zebra®sh embryos. Each one-cell stage embryos was injected with M 2 or EGFP dsRNA, and then incubated at 28.58C until the heart rate was measured at room temperature. The same embryo was assayed for CCh-induced bradycardia at 56, 72 and 96 h.p.f. CCh-induced bradycardia was performed as described in Methods. The ratio of the heart rate is de®ned as in Figure 6 legend. The data represent the mean and the s.e.mean for three independent experiments, each with 8 ± 10 individuals. A dierence between the M 2 dsRNA and the wild-type, or EGFP was considered signi®cant with P50.05 (*, + ) or P50.01 (**, ++ ) using Student's t-test. 74 M CCh at room temperature. The ratio of heart rate of CCh-induced bradycardia is de®ned as in Figure 6 legend. The data represent the mean and s.e.mean from three independent experiments, each with 8 ± 10 individuals. A dierences in the M 2 MO compared to the M 2 4 mp MO control was tested with the Student's t-test and considered signi®cant with P50.05 (*) or P50.01 (**).
British Journal of Pharmacology vol 137 (6) Zebrafish M 2 mAChR D.J.-Y. Hsieh and C.-F. Liaocommonly believed to be the only functional mAChR found in the mammalian heart (Peralta et al., 1987b) , M 1 receptor mRNAs have been identi®ed in guinea-pig and rat ventricular cardiomyocytes (Colecraft et al., 1998; Gallo et al., 1993) and M 3 and M 4 receptors were reported to probably have a functional role in the control of K + channels in atrial tissue of the dog heart (Shi et al., 1999) . In order to analyse which subtype(s) of mAChR mediate the CCh-induced bradycardia, we utilize the pharmacological approach with various muscarinic antagonists to study their eect on CCh-induced bradycardia in zebra®sh embryos (Figure 6 ). The results demonstrated that M 2 -speci®c antagonists had stronger blocking eect. However, since the subtype-selective antagonists are not highly speci®c, we further explore the muscarinic regulation of heart rate with molecular approaches.
RNA i is a method whereby an injection of dsRNA into cells results in the degradation of the existing cognate mRNA and repression of further synthesis. This technique is receiving increased attention (Gura, 2000) . The success of RNA i in the invertebrates, Caenorhabditis elegans and Drosophila, is well known and now it has been extended to targeting gene expression in the vertebrate mouse (Wianny & Zernicka-Goetz, 2000; Zernicka-Goetz, 2000) . Some studies indicate that RNA i can speci®cally knockdown gene expression in the zebra®sh (Wargelius et al., 1999; Li et al., 2000) , although it has nonspeci®c eects on early zebra®sh development such as causing abnormal phenotypes (Oates et al., 2000) . When injected at a low concentration (5.25610 6 molecules), the nonspeci®c eects can be minimized. In the RNA i experiments, we found that M 2 dsRNA could block CCh-induced bradycardia (Figure 7 ) and that the M 2 dsRNA is stable in zebra®sh embryo for about 3 days.
Additionally, MOs have produced well-accepted phenotypes in the analysis of zebra®sh embryonic development (Nasevicius & Ekker, 2000) . MOs function through an RNase ± Hindependent mechanism by blocking translational initiation (Summerton, 1999) . We found that the antisense M 2 MO could both increase the basal heart rate and blocked the CCh-induced bradycardia (Figure 8 ). In addition, the CCh-induced bradycardia was reversed by atropine, methoctramine, or 4-DAMP (100 mM) (Figure 6 ). The heart rate re¯ects the balance between sympathetic and parasympathetic nervous system (Swynghedauw et al., 1997) . The vagal tone may decrease the heart rate and the antagonist atropine can accelerate the heart rate. It has been reported that mouse has no vagal tone, and atropine injection does not increase the heart rate as it does in humans (Swynghedauw et al., 1997) . The basal heart rate was not increased on the M 2 mAChR knockout mice (Stengel et al., 2000; Birdsall et al., 2001) . We found, however, that M 2 MO can signi®cantly increase the basal heart rate in zebra®sh. This novel ®nding in zebra®sh further suggests species-dependent M 2 mAChR mediated regulation of the basal heart rate. Besides, after¯uorescein tagged MO injection (8 ng per embryo), the¯uoresence in embryo can be seen for one month (Mark Chen, personal communication) . Thus, the MO is much more stable than dsRNA in zebra®sh embryo. It is also easy to perform double knockdowns with MOs. This will help to solve the arduous problem of gene redundancy and non-speci®c agonists or antagonists.
We have also cloned the zebra®sh M 5 mAChR gene. However, the M 5 mAChR transcripts were not detectable in the zebra®sh heart by the whole mount in situ hybridization. The in vivo pharmacological experiments, RNA i or MO knockdown studies showed M 5 mAChR had no eect on CCh-induced bradycardia and basal heart rate at 72 h.p.f. embryos (data not shown). M 5 mAChR lacked functional signi®cance in the regulation of heart rate.
Our study represents the ®rst paradigm of application of zebra®sh in mAChR pharmacology research. Our approaches can be applied to study other receptors and drugs involved in the regulation of heart rate.
